EmVenio Research Expands in the UK
With 10 mobile community research sites in the US, the move expands the organization’s international reach.
EmVenio Research, in collaboration with UK-based EMS Healthcare, will establish and operate commercial clinical trials in 10 mobile sites identified by EMS, across England, Wales, and Scotland. Each of the sites will be supported by a dedicated local workforce. EmVenio will be responsible for full clinical oversight, with principal and sub-investigators, and team leaders, and will oversee clinical trial operations and data management.
EmVenio currently operates research in 10 mobile community research sites across the United States.
Keith Austin, CEO of EMS Healthcare, said in press release, "A recent independent review of commercial clinical trials by Lord James O'Shaughnessy acknowledged the crucial role of mobile clinics in delivering trials with more diverse participation. We believe this initiative will attract more pharmaceutical sponsors to carry out trials, which will have a significant impact on both the U.K. economy and the health of our population."
Reference: EmVenio Research expands internationally with 10 research sites in the UK. DURHAM, N.C., June 20, 2023 /PRNewswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
